Public Comment Phase on Warfarin Genetic Test Reimbursement Ends Tomorrow | GenomeWeb
NEW YORK (GenomeWeb News) – The Center for Medicare and Medicaid Services will stop taking public comments tomorrow, Sept. 3, about whether Medicare should provide reimbursement for DNA tests for the common anticoagulant warfarin.
Tomorrow marks the end of a public comment phase begun a month ago as part of a CMS National Coverage Analysis investigation to determine whether there is sufficient evidence that a pharmacogenomic test for warfarin is effective enough for coverage.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.